The rumors are now a reality. Abbott Laboratories is acquiring Exact Sciences for $21 billion, marking what could be the biggest medtech deal of 2025. The deal’s announcement comes less than 24 hours ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...